Glenmark Pharma launches Bumetanide injection vials

Glenmark Pharma has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) single-dose vials and 2.5 mg/10 mL (0.25 mg/mL) multi-dose vials, the generic version of Bumex Injection, 0.25 mg/mL, of Validus Pharma, a statement from the company notified.

According to IQVIA sales data for the 12-month period ending November 2022, the Bumex injection, 0.25 mg/mL market achieved annual sales of approximately $16.5 million, the statement added.